Here, we report that LSD1 and G9a synergistically promote cell growth in ESCC, and we provide preclinical evidence supporting the combined inhibition of LSD1 and G9a as a novel and promising strategy for treating ESCC. Here, EHMT2 is linked to esophageal squamous cell carcinoma.